No news is not bad news5 Jul 2022 16:54
Oh dear, it seems some would rather vent their angst on this forum, rather than believe the last update (less than 2 months ago). If anything had changed since then they would be obliged to announce it in a timely manner. So for the sake of balance, to counteract the negative sentiment on here lately, here is the summary from that update, read it and revel in the stream of good news coming our way very soon:-
· The conclusion of the board review is that the Company is on track to achieve its commercialisation targets following positive engagement with counterparties during the past month. The Company therefore intends to progress with each of its core projects as well as with the development of bioMSAR™ fuel and its derivatives.
· MSC - Quadrise recently met with MSC executive management in Cyprus and both parties are now working to finalise an agreement covering the LONO trial programme aboard MSC container shipping vessels and the subsequent commercial framework. The conclusion of the board review is that the Company is on track to achieve its commercialisation targets following positive engagement with counterparties during the past month. The Company therefore intends to progress with each of its core projects as well as with the development of bioMSAR™ fuel and its derivatives.
· Morocco - an updated Material Transfer and Cooperation Agreement with our international chemicals and mining client is now expected to be signed this month ahead of an MSAR® combustion trial that is expected to conclude early Q3 2022.
· Utah - following signing of Commercial Development Agreement ("CDA") in April 2022, Quadrise and Valkor have commenced preparatory steps under Phase 1 of the CDA to identify target consumers of MSAR® and bioMSAR™ fuel.
· Testing with Aquafuel this quarter will conclude the bioMSAR™ engine efficiency optimisation work, with results expected in early Q3 2022.
· Discussions are underway with several candidate sites in Panama and Honduras for MSAR® and bioMSAR™ power plant trials later in 2022.